Vitamin D Adequacy and Improvements of Comorbidities in Persons with Intellectual Developmental Disabilities

Sunil J. Wimalawansa*

Cardio Metabolic Institute, New Jersey, USA

Corresponding Author:
Sunil J. Wimalawansa
Cardio Metabolic Institute
North Brusnwick, New Jersey, USA
Tel: 7323056537
E-mail: [email protected]

Received date: April 28, 2016; Accepted date: June 16, 2016; Published date: June 23, 2016

Citation:Wimalawansa SJ. Vitamin D Adequacy and Improvements of Comorbidities in Persons with Intellectual Developmental Disabilities. J Child Dev Disord. 2016, 2:3.doi: 10.4172/2472-1786.100030

Visit for more related articles at Journal of Childhood & Developmental Disorders


The prevalence of vitamin D deficiency is alarmingly high among people with developmental disabilities. In addition to enhancing mineral metabolism, vitamin D affects neuro-modulation, muscle coordination, immunity, infections and autoimmune disorders. Peer-reviewed papers from PubMed, Medline, and other research databases were searched using key words to collate relevant evidence in preparation of this evidence-based review. Per the guidelines from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), general interpretations of results are included taking into consideration the risk–benefits, broader evidence, and implications for practicing clinicians. Many clinicians consider the minimum level of serum 25-hydroxy vitamin D [25(OH)D] required for optimal health in the normal population to be 30 ng/mL (75 nmol/L), whereas a lesser number consider the level to be 20 ng/mL. However, evolving data suggest that for vulnerable populations, such as those with autoimmune disease, cancer, cardiovascular diseases, metabolic syndrome, and persons with developmental and intellectual disabilities, 40 ng/mL (100 nmol/L) might be considered the minimum level. To reach this level, most people requires adequate sun exposure and/or a daily oral supplementation of between 1,000 and 5,000 International Units of vitamin D. This review explores vitamin D requirements for the musculoskeletal and non-skeletal systems and its adequacy in relationship to common disorders affecting persons with intellectual disabilities.


Adequate vitamin D is essential for optimal health [1,2]. Vitamin D deficiency is one of the most common nutritional deficiencies in the world that can be easily treated. Emerging data suggest that the beneficial effects of vitamin D extend beyond the regulation of calcium and phosphorus homeostasis. Although no randomized controlled clinical trial data exist, the increasing volume of data reported suggest the physiological importance of vitamin D in systems other than the musculoskeletal system.

The prevalence of vitamin D insufficiency is higher in certain vulnerable groups [3], such as those who are obese, those with impaired gastrointestinal absorption of vitamin D, those taking medications that enhance cytochrome P450 activity in the liver [4,5], and persons who are institutionalized, such as in nursing homes [6,7]. People with disabilities, including longterm residents innursing homes, rehabilitation centers, Group Homes, and disability centres, have high prevalence of vitamin D deficiency [8-10]. Of the 30 leading causes of death (in 2010) in the United States, 19 have been linked to low vitamin D status [11]. These include cardiovascular disease, cancer, Alzheimer disease, diabetes mellitus, and falls and fractures in the elderly.

Because of multiple pathologies, coexisting disorders, and the intake of multiple medications that are known to enhance catabolism of vitamin D, persons with medically complex developmental disability (MCDD) [12] experience more comorbidities that are exacerbated by vitamin D inadequacy. These patients are likely to require longer exposure to ultraviolet B-light (UV-B) and/or higher doses of vitamin D supplements to maintain healthy serum 25-hydroxy vitamin D [25(OH)D] levels.

Accumulating data also support the need to maintain a higher serum 25(OH)D level in persons with MCDD, than in healthy people for better health outcomes and to minimize comorbidities associated with vitamin D deficiency [6,13].

The incidence and prevalence of vitamin D deficiency and associated complications in persons with MCDD are different from those of the healthy population [14]. This review addresses the lack of knowledge regarding the relationships between serum vitamin D levels and musculoskeletal disorders and non-skeletal disorders, the potential for mistaken treatment of patients with osteomalacia with potent antiresorptive agents, and the relationship of vitamin D statuses with broader potential health outcomesin patients with MCDD.

Common causes leading to vitamin D deficiency

The persons with MCDD consists of groups of people with a variety of neurodevelopmental disorders and developmentally induced physical and intellectual disabilities. Limited data suggest a high incidence of vitamin D deficiency among persons with MCDD [15,16]. Whether vitamin D deficiency aggravates existing comorbidities and/or initiates new conditions in this highly ulnerable population is not clear. Many patients with MCDD take multiple medications, such as anticonvulsant drugs and glucocorticoids, that enhancethe catabolism of vitamin D. Doing sofurther reduces the blood levels of vitamin D and its stores [17]. This requires persons with MCDD to have a longer exposure to UV-B and/or higher doses of vitamin D supplements than the doses usually recommended for the general population to maintain serum vitamin D levels.

In the above group of persons, vitamin D inadequacy is attributable to a combination of insufficient sun exposure, suboptimal dietary intake and supplements, enhanced catabolism of vitamin D, and having multiple comorbidities. In general, less sun-exposure is in part attributable to staying predominantly indoors, concerns about skin cancer, climatic changes and related issues, pollution [18], lifestyle, obesity, and changes in dietetic patterns [19]. Figure 1 illustrates the natural cycle of generation of vitamin D. The figure also illustrates the importance of sun exposure as a natural means of generating endogenous vitamin D.


Figure 1: The generation of pre-vitamin D, 25(OH)D, the activation steps of 25(OH)D to the active hormonal form, 1,25(OH)2D, and their inactivation steps are illustrated [27].

Vitamin D requirements

Many clinical studies of supplemental vitamin D have been nonconclusive because the provision of a substance to those who are already sufficient does not alleviate anything. To observe differences, intervention should be offered to those who are vitamin D deficient [20]. Researchers have reported a wide range of healthbenefitsof vitamin D[21,22]. Nevertheless, only a small number of deficient and insufficient persons are supplemented with vitamin D. This is in part hampered by the high cost of measuring serum 25(OH)D and not making the right diagnosis [23].

When the rates of insufficiency and deficiency reach more than 70% in a community, one could argue (for cost-effectiveness purposes), that supplements can be offered (and to encourage sun exposure) in the absence (or in lieu) of measuring serum 25 (OH)D levels. Safe sun-exposure is the best option to raising serum vitamin D levels, but in those with MCDD, this often is not easy or practical.

Considering the logistical difficulties, costs, and the established higher safety limits of intake, every resident in high-risk community such as in a residential facility could be offered a combination of improved (supervised) safe sun-exposure,food fortification with vitamin D ,and acceptable supplemental dose of vitamin D and other micronutrients. Considering the potential of significant reduction of falls and injuries including fractures, this approach is likely to be cost-effective.

Meta-analyses data on the adverse effects of vitamin D

In a meta-analysis of data that used vitamin D doses from 400- 7,000 IU per day or 8,400 - 54,000 IU per week with followup periods as long as 4 years, no adverse effects of vitamin D treatment were reported [24]. However, these studies were not designed to assess the true dose-responses or dose-related harm. None of these studies reported any differences of rates of serious adverse events, including hypercalcemia and hypercalciuria, or withdrawal because of adverse events [23,24].

In another meta-analysis, none of the 17 trials included had a higher incidence of hypercalcemia in treated versus control participants [4,25]. The numbers of cases of hypercalcemia were low in both groups, and seven of the trials reported no cases of hypercalcemia or kidney stones, in vitamin-D–supplemented groups. Overall, studies suggest the safety of using vitamin D doses as high as 10,000 IU, daily [4,25].

The upper daily safe limit for average healthy people is considered 5,000 IU a day, and toxicity does not develop until serum levels reach more than 125 ng/mL (>312 nml/L) [4,25]. Toxicity may manifest in persons who consume vitamin D in doses excess of 50,000 IU daily for several months. Toxicity would not appear unless serum 25(OH)D levels exceeds and sustained above 100 ng/mL (250 nmol/L) for a period [26].

Thus, it is safe to treat individual residents in developmental disability facilities, using orally administered doses of vitamin D between 2,000 and 4,000 IU a day or 50,000 IU twice a month; adverse effects are caused by much higher doses [8,25,27].

Guidelines and normal ranges

The rate of diagnoses for vitamin D deficiency has markedly increased since 2007 [28]. Most diagnoses concluded were for non-specific diseases suggesting that measurements were ordered as a screening process, instead as a diagnostic process.

In recent years, several organizations [e.g., The Institute of Medicine (IOM) [29], The Endocrine Society (TES) [4], The American Geriatrics Society [30], American Academy of Developmental Medicine and Dentistry [14], and ad hoc vitamin D groups [22,31] have developed clinical practice guidelines.

However, based on the articles reviewed and included in the guideline document and the intended population(s), the recommendations vary. For example, the IOM guideline defined vitamin D insufficiency as serum 25(OH)D levels between 11 and 20 ng/mL and vitamin D deficiency as a 25 (OH)D below 10 ng/ mL [29]. TES defined vitamin D deficiency as a 25(OH)D level less than 30 ng/mL and vitamin D insufficiency as a level between 21and 29 ng/mL [4].

The IOM recommendations were intended for a healthy population in North America for making public health decisions [29] and not intended to be applied in the treatment of patients [32]. The TES guidelines are for managing individuals and patients in general [4]. However, neither set of recommendations addressed vulnerable groups or subgroups of patients. The latter groups require special guidelines and in most cases likely to require a higher minimum serum 25(OH)D level than that recommended levels by TES, 30 ng/mL [4,14,19,25,33].

Many experts agree that the minimum serum 25(OH)D level of 30 ng/mL is adequate for normal healthy individuals, but highrisk populations, including persons with MCDD, likely need the optimal serum vitamin D levels greater than 40 ng/mL [14,17,27], as discussed later in this text. In this regard, in two separate African tribes examined, the pastoral Masai and the hunter– gatherer Hadza tribes, the average serum 25(OH) vitamin D level was 46 ng/mL, suggesting that optimal serum 25 (OH)D level is beyond 40 ng/mL [34,35].

It is important to understand that those with MCDD are at high risk for multiple chronic health issues, some of which may be alleviated in the presence of vitamin D adequacy. Considering that theoverwhelmingmajorityof MCDD persons are vitamin D deficient, The American Academy of Developmental Medicine & Dentistry (AADMD) commissioned a Vitamin D-Task Force to develop specific guidelines and recommendations for persons with intellectual and developmental disability.

The Task Force recommended minimum serum 25(OH) D levels of 40 ng/mL for persons with MCDD [14]. The Task Force recommended that 25(OH)D concentrations needed for optimal health in persons with MCDD are between 30 and 50 ng/ mL (75-125 nmol/L), which can be achieved safely using orally administered vitamin D3 supplements up to 4,000 IU/day and/or sensible exposure to solar UVB radiation [14].

Vitamin D supplementation

Many residents in developmental disability centers receive between 400 and 600 IU of vitamin D a day through their pharmacies. Since the diet provides too little vitamin D, in the absence ofsun exposure, such small doses enable very few residentsto achieveserum 25(OH)D levels beyond 30 ng/mL. In addition, most persons with developmental and neuro-disabilities receive a number of medications that enhance the catabolism of vitamin D [8,27,36].

Several publications support the necessity of having serum 25(OH) D levels greater than 40 ng/mL to alleviate certain diseases. Such diseases include some diseases affecting the musculoskeletal system [25], management of breast [37] and other cancers [38], Crohn’s disease [39], type 1 diabetes [40], type 2diabetes [41], infections [42], multiple sclerosis [43], and systemic lupus erythematosus [44].

Persons with MCDD who have multiple comorbidities are also likely to require higher intake of vitamin D(e.g.,between 2,000 and 5,000 IU daily to keep the serum 25(OH)D levels between 40 and 60 ng/mL) than does the general population to maintain serum vitamin D levels above 30 ng/mL [14,32].

Most people with MCDD living in disability centers are vitamin D deficient, but a few have adequate vitamin D levels. However, giving vitamin D doses such as 4,000 IU a day or 50,000 IU twice a month is highly unlikely to raise the serum vitamin D levels above 60 ng/mL even in those with adequate levels before supplementation. Levels greater than 125 ng/mL are considered toxic [4,31]. In addition to the broader benefits from vitamin D adequacy and the disadvantage of high cost of vitamin D testing, many patients with MCDD would not cooperate with venipuncture. These factors support the argument that persons with MCDD could be safely treated with routine oral vitamin D3 supplementation.

Cost-effective approaches to alleviate vitamin D deficiency in institutionalized persons

For most people in the world, diets do not provide more than 500 IU of vitamin per day, but the daily requirements are much higher [45,46]. In the absence of adequate exposure to UVB, many people would not be able to obtain adequate vitamin D for optimal physiological functions. For example, using the TESrecommended minimum level of vitamin D of 30 ng/mL, more than 50% of children and adults in North America were reported as vitamin D insufficient [27,47,48], in part, because of sun avoidance and inadequate UVB availability during the winter months. Thus, in the absence of adequate exposure to UVB rays, many become vitamin D insufficient or deficient. The prevalence is particularly high among persons with MCDD and those who are housebound.

For most persons with MCDD, the administration of vitamin D at doses less than 1,000 IU a day or 50,000 IU a month, is insufficient to achieve serum 25(OH)D levels greater than 30 ng/ mL (75 nmol/L) [49]. Because of the marked fluctuation of serum levelswhen vitamin Dis administered at infrequent than monthly intervals, such a regimen is less beneficial even though it may help to attain the target levels of serum 25 (OH)D for a short period [25,33,50]. However, the goal should be to maintain the desirable, steady-state serum 25 (OH)D level, throughout the year.

Routine testing of serum vitamin D is inconvenient for persons with MCDD. It only increases cost withlittlebenefit. For this particular population, administering one capsule of 50,000 IU vitamin D3 once every 2 weeks ($0.30 per capsule × 26 capsules per year) would cost less than $10 per year.

Considering virtuallyno adverse effects with such a dose and the potential benefit in decreasing morbidities, this is a highly costeffective and practical approach in this population.

Key actions of vitamin D on musculoskeletal health

Vitamin D facilitates intestinal absorption of calcium and maintains optimal skeletal health. It is also necessary for mineralization and maintenance of the skeleton, proper reflexes, and neuromuscular coordination. Even subclinical vitamin D deficiency can increase sway and falls in the elderly and vulnerable people [51]. In addition, it may exacerbate osteoporosis through vitamin D-deficiency-induced secondary hyperparathyroidism and consequent increased osteoclastic bone resorption [19,52,53], thus increasing fracture risks.

In addition, an inverse relationship exists between serum PTH and 25(OH)D levels up to about 50 ng/mL, plateauing beyond that [54,55]. Higher PTH levels are associated with increased morbidity and mortality, in part because of increased incidences of cardiovascular disease [56-61]. Figure 2 illustrates an inverse relationship of serum 25(OH)D and serum PTH levels. Vitamin D is important for all tissues in the body and the development and mineralization of bones. Rickets and osteomalacia are manifestations of severe, chronic vitamin D deficiency. In children, vitamin D deficiency causes rickets, resulting in softening of bones, leading to skeletal deformities. In adults, it leads to osteomalacia, muscular weakness, falls, and fractures [62-69]. Compared with the healthy population, people with MCDD have more comorbidities, including osteomalacia [9,70] and osteoporosis [71-73], and increased incidence of falls and fractures [74-76].


Figure 2: Inverse relationship between the serum 25(OH)D and serum intact PTH (parathyroid hormone) levels. Median values are given, and individual scatter data points have been removed to improve clarity (median data from a number of studies) [183-185] [graph was modified from [27]]. With increasing serum 25(OH)D, the serum PTH levels continue to decrease below 30 pg/mL and seem to stabilize around 20 nmol/L [46, 54, 55].

Use of antiresorptive agents in persons with MCDD: In recent years, the potent antiresorptive agents, bisphosphonates and denosumab have become popular for the treatment of low bone mineral density (BMD) as measured by dual-energy x-ray absorptiometry (DXA). This is particularly disturbing in institutionalized adults with intellectual disabilities, who have a high incidence of osteomalacia. Considering that patients with vitamin D deficiency often experience poor response to bisphosphonates, it is questionable whether many of these patients need or benefit from (or may be even harmed by) treatments with potent anti-osteoporosis pharmaceuticals [72].

For example, in an observational study, favorable response to bisphosphonates was seen more frequently in patients with serum 25(OH)D levels greater than 33 ng/mL [77]. In this study, those with 25(OH)D levels less than 30 ng/mL, only 21% responded, 50% responded in those with levels between 30 and 40 ng/mL, and 77% responded in those with serum 25(OH) D levels greater than 40 ng/mL, as documented by increasing BMD [77]. Data suggests an increased BMD associated with increasing levels of serum vitamin D, following anti-osteoporosis therapy; however, this needs to be confirmed by other studies.

Misinterpretation of BMD data leading to mistreatment in patients with MCDD

Age has a profound impact on bone loss and the risk of fractures. As a result, the prevalence of osteopenia and osteoporosis as demonstrated by measuring BMD increases with advancing age in all skeletal sites that are vulnerable to fragility fractures [53]. Because most persons with MCDD are relatively inactive, their peak-bone mass and the BMD is lower, and have a higher risk of fractures. However, just because the BMD is low does not mean that a person is osteoporotic, particularly in the MCDD population, in whom the prevalence of vitamin D deficiency and osteomalacia are high. Consequently, instead of having their vitamin D deficiency and underlying osteomalacia corrected, many of these patients are treated inappropriately with potent antiresorptive agents, such as bisphosphonates and denosumab, because vitamin D deficiency is not diagnosed. This preventable error should be avoided with future medications, such a odanacatib. In this population, many have low BMD in coexistence with osteomalacia and thus, should be treated with vitamin D

supplements first to correct their vitamin D deficiency. BMD measurements obtained using DXA scanning cannot differentiate osteoporosis form osteomalacia. If the lower BMD is primarily caused by osteomalacia, correction of vitamin D deficiency would rapidly increase BMD by facilitating mineralization of existing uncalcified osteoid. Therefore, in these patients the “diagnoses” of osteopenia and osteoporosis are being made erroneously, using numerical BMD values generated though DXA, which is not capable of differentiating osteomalacia from osteoporosis. Therefore, in the absence of correcting vitamin D deficiency and associated osteomalacia, the uses of potent antiresorptive agents can be harmful. Neither the DXA machine nor physicians who interpret these data can differentiate between osteomalacia and osteoporosis based on BMD data (i.e., grams of mineral per square centimeter or the T-scores) [27]. As a result, when these patients are mistakenly labelled as having osteoporosis, physicians are inclined to treat them with potent antiresorptive agents, such as bisphosphonates, denosumab (or odanacatibindue course), which is unscientific and inappropriate.

Importance of correcting vitamin D deficiency before starting antiresorptive therapy

Underlying vitamin D deficiency should be corrected by giving adequate doses of vitamin D, before considering the use of antiresorptive therapy [8]. After improving the serum vitamin D levels to an optimal range (e.g., greater than 40 ng/mL in persons with MCDD), it is reasonable to repeat the DXA scan in 6 months or a year later, using the same machine. If the BMD remains low after correction of vitamin D deficiency and there are no additional correctable secondary causes present, it is reasonable to consider prescribing an anti-osteoporosis agent,if the patient is at high risk for fractures.

Unfortunately, because of the lack of a basic understanding of underlying pathophysiology, a large number of patients with MCDD are treated with potent anti-osteoporosis therapies that may not benefit but harm them. In the presence of vitamin D deficiency, such therapies have little or no benefit on fracture reduction. In fact, such therapy may aggravate or precipitate osteomalacia, develop hypocalcemia, and worsen seizures. In addition, the underlying issue of vitamin D deficiency continues to increase comorbidities.

Persons with MCDD have higher incidence of falls and fractures

Postural swing has been linked to increased risk of falls in those with serum 25(OH)D levels below 12 ng/mL. Treatment with vitamin D improved sway and decreased the incidence of falls in the elderly [78]. People with MCDD often have osteomalacia [9], osteopenia, or osteoporosis [70] and low bone mass [33,79]; collectively, all of these increase fracture risks. Having strong bones and good neuromuscular control are the key to minimizing falls and fractures.

For example, in individuals with vitamin D deficiency and increased postural sway, treatment with 8,400 IU of vitamin D3 once a week reduced the sway [80]. Evidence from other randomized clinical trials supports that vitamin D supplements improve muscle strength and overall function of the elderly and reduce the risk of falls in the elderly. These findings support the notion that vitamin D supplements improve overall neuromuscular function and coordination [81].

Falls among disabled people occur frequently, especially in those with low serum 25(OH)D levels [82]; such people sustain a higher incidence of fractures [83]. The combination of disabilities and vitamin D deficiency further increases the risk of falls [6,13,84]. This is a major issue in persons with neurodisabilities, who are more vulnerable to fall and fracture [36,73,75,85,86].

Falls can be reduced with the correction of vitamin D deficiency

The frequency of falls in the elderly and disabled can be reduced by correcting vitamin D deficiency [80]. Comorbidities, including the consumption of certain medications (e.g., psychotropic drugs), visual and hearing impairment, axial orthopedic disabilities, peripheral nerve dysfunction, balance issues, and muscle weakness, increase fall risks [87]. In the MCDD population, muscle weakness and poor coordination are particularly important risk factors for falls and fractures that decrease with vitamin Dsupplementation [78,87-100]. Thus, it is important to address this issue in all osteoporosis and fracture-prevention programs, and by geriatricians [8,19,53].

A meta-analysis of double-blind, randomized clinical trials revealed that supplementation with vitamin D reduced the fall risks in institutionalized individuals by more than 20% [87-89,101,102]. Thus, fall reduction must be given a priority in all residential care facilities. Several meta-analyses of randomized clinical trials confirmed a significant reduction of falls risk with vitamin D supplementation [98,103,104]. Therefore, optimizing serum 25(OH)D levels above the minimal recommended levels using vitamin D supplementation or by UVB exposure in patients with MCDD should be considered as standard of care in clinical practice.

In addition to vitamin D supplements, corrective measures should include environmental modifications, including removal of hazards and obstacles, the provision of appropriate railings, hearing aids, and corrective eyeglasses. In addition to vitamin D deficiency, arthritis, visual and hearing impairment, central or peripheral neuralgic dysfunction, and peripheral neuropathy increase the risk of falling. Although some researchers have suggested that analogues of vitamin D may be more effective than vitamin D for fall prevention [105], this has not been proven in other clinical studies.

Correcting vitamin D deficiency

Available doses of vitamin D3 range from 1,000-50,000 IU as gel capsules; they are inexpensive and well tolerated. Adequate doses improve muscle function and reflexes and thereby effectively prevent falls and fractures [78,87-100].

Vitamin D plays an important role in neuromuscular control, which reduces the risk of falls and consequently fractures [106]. Improving vitamin D status is an important modifiable risk factor for reducing falls and fractures [80], particularly in those with MCDD. Because of the relatively shorter half-life of vitamin D2, vitamin D3 is preferred and should be administered no less frequently than once monthly [8,19].

Vitamin D may come from UV exposure, dietary intake, or supplements. The input from all sources required each day to meet physiological needs and support optimal health is estimated to be roughly 6,000 IU/day [107,108]. It has been estimated that raising the minimum year-round serum 25(OH)D level between 40-60 ng/mL (100-150 nmol/L)would prevent approximately 58,000 new cases of breast cancer and 49,000 new cases of colorectal cancer each year [109]. Such levels are also expected to reduce the case-fatality rates by half, in patients with breast, colorectal, or prostate cancer [110]. There is no significant risk associated with taking 2,000-5,000 IU vitamin D3 per day or increasing the population serum 25(OH)D level to greater than 40 ng/mL.

Extra-skeletal benefits of vitamin D

Hundreds of research reports indicate that 25(OH)D has a number of beneficial effects on the extra-skeletal tissues, including the and cardiovascular system [111-116]. Most of the relationships reported between serum 25(OH)D and extra-skeletal benefits are associations and do not provide “cause–effect” relationship [117]; however, supportive evidence continues to accumulate.

One needs to be cognitcient that vitamin D deficiency could be a “marker” of poor nutrition and/or ill health [7,8,27,84]. These associations can be affected by many confounding factors, such as place of living, diet, smoking, and supplements [29,118]. In contrast to the aforementioned, data from two recent systematic reviews found no evidence that vitamin D supplements modify extra-skeletal conditions [119,120]. Figure 3 illustrates the associations and interactions between vitamin D and various disorders.


Figure 3: The complex interactions between vitamin D and various bodily functions and organ systems. Adequate vitamin D could prevent or improve many disorders [27].

Common disorders that are aggravated by vitamin deficiency

Muscle weakness and sarcopenia have an inverse correlation with serum 25(OH)D levels [80]. There are abundant vitamin D receptors (VDR) in muscle cells that increase with physical activity [121]. However, the expression of muscle VDR levels declines with age [92] and is associated with sarcopenia. In addition to aging, inactivity and vitamin D deficiency contribute to the development of muscle weakness and sarcopenia, enhancing fall risks; these can be reversed with vitamin D.

Epidemiological studies have suggested links between serum 25(OH)D levels (and exposure to sunlight) and the incidences of breast [122-124], colon (digestive tract), prostate, and ovarian cancers; non-Hodgkin’s lymphoma; and certain leukemias [111,125-130]. However, whether the incidence of cancer would decrease with normalization of vitamin D status is not known.

Persons with MCDD are predisposed to a higher incidence of infections, perhaps as a consequence of impairment of the immune system secondary to vitamin D deficiency, which enhances the susceptibility to viral and bacterial infections, including tuberculosis [131,132]. Evidence supports that adequate serum vitamin D levels enhance immunity. Indirect bactericidal effects of vitamin D that manifest via the induction of cathelicidin may also contribute to this [133]. Research alsosuggests an association between low serum vitamin D levels and inflammatory bowel diseases [134-137].

Other muscular and neurological defects: Persons with MCDD have a high incidence of swallowing difficulties and neurological defects. Dysphagia is common among persons with developmental disabilities for a number of reasons, including the widespread use of neuroleptic medication, abnormal posture, non-cooperation in swallowing, yeast infections, and gastroesophageal reflux disease.

Dysphagia can lead to aspiration pneumonia, malnutrition, and sarcopenia. Although a connection between vitamin D deficiency and swallowing deficits is biologically plausible, there are no causative data available on vitamin D status and the risk of dysphagia.

Considering the high prevalence of vitamin D deficiency in persons with MCDD, it is plausible that decreased muscle function and coordination caused by vitamin D deficiency may be causally related to the increased incidence of dysphagia observed [138,139]. In addition, suboptimal vitamin D levels may affect the severity of over-active bladder in patients with chronic disabilities. Because of inactivity and muscle weakness, some people with MCDD develop abdominal obesitythat worsen in the presence of vitamin D deficiency [140].

Pulmonary function is known to worsen in those with vitamin D deficiency. Regarding chronic lung diseases, whether the decline of respiratory muscle function is attributable to vitamin D deficiency, chronic silent aspiration from oropharyngeal dysfunction, chronic obstructive airway disease and chronic inflammation, or impaired lung tissueremodeling, is not known [141,142].

VDR and vitamin D-associated enzymes are expressed in the central nervous system, particularly in areas affected by neuro-degenerative disorders, especially in the hippocampal region [143]. Vitamin D deficiency has also been correlated with worsening Alzheimer disease and memory, both of which can lead to increased falls and fractures [144].

Autism, attention deficit syndrome, and oral health: Accumulating community-based evidence indicates that vitamin D deficiency may enhance the risk for and the progression of autism [85,145,146]. A study of children in the United States reported significant inverse correlations of solar UVB exposure (a proxy for vitamin D production) with an increased prevalence of autism [145]. It has been suggested that vitamin D may regulate cerebral serotonin synthesis, which may lead to an increased risk of autism [147]. While this may not be the only mechanism, whether correcting vitamin D status would improve the symptoms of autism remains unknown [85].

People with intellectual and developmental disabilities have an increased incidence of attention deficit–hyperactivity disorders (ADHDs) [148]. Affected persons are known to have lower serum 25(OH)D levels than do control subjects [149,150]. A larger, community-based randomized clinical trials are needed to assess whether vitamin D supplementation would alleviate the symptoms of ADHDs [151]. There are many theories regarding the beneficial effects of vitamin D in the alleviation of developmental disorders that affect the central nervous system; these need further investigation.

Poor oral hygiene and dental caries are common among persons with developmental disabilities. A recent meta-analysis of controlled clinical trials reported significant benefit of vitamin D supplementation on oral health [152]. Vitamin D is also shown to reduce the risk of dental caries [153]. Nevertheless, low vitamin D levels could be a surrogate marker for poor oral hygiene. Also be in the and low socioeconomic status, thus, unaffordability and lack of access (insurance issues) to dentists and oral hygienists. Vitamin D deficiency has also been shown to be associated with premature tooth loss and escalating periodontal diseases [154,155].

Other conditions commonly present in persons with MCDD

In addition to common autoimmune disorders, multiple sclerosis [156], Gaucher disease (type 1-lysosomal storage disorder) [157], Williams syndrome [73], Down syndrome [72,75], and many other disorders are known to be associated with low serum 25(OH)D levels [36,72,75]. There are ongoing studies to test the postulated associations between various diseases with vitamin D. Other studies have demonstrated an inverse relationship between 25(OH)D levels and the all-cause mortality rates [158,159] and frailty [160,161].

Meta-analysis data show that an increase of serum 25(OH) D levels from 22 ng/mL to 42 ng/mL (54 to 105 nmol/L) was associated with a statistically significant, 15% reduction in incidence of cardiovascular diseases [109] and decrease of breast and colorectal cancer incidences by 30% (Table 1) [38,162].

Disease or Disorder Minimum Serum 25(OH)D Required References
Osteomalacia Serum 25(OH)D levels 15 ng/mL [22,31,163,164]
Muscular functions Fall prevention Dental health and oral hygieneCardiovascular protectionAll-cause mortality Serum 25(OH)D levels 30 ng/mL [22, 31, 164-170]
Prevention of autoimmune disorders, cancer, osteoporosis, type 2 diabetes, infections and obesity Serum 25(OH)D levels 40 ng/mL [22,31,162,164,166,171-175]
Subgroups of people who would be benefited by maintaining their serum 25(OH)D levels above 40 ng/mL Those who are obese, have metabolic syndrome or autoimmune disorders, those in residential-care facilities, and those with intellectual and developmental disabilities [22,31,70,162,164,166,171-175]

Table 1: illustrates a simplified version for understanding the minimum serum levels of 25(OH)D required to overcome various ailments in broader subgroups of people.


It is important to note that not all vitamin D-related clinical studies are positive. Although some are ambiguous, few showed harm when individuals were treated with high doses of vitamin D, but such is a minority [176-178]. This review describes pros and cons of measurements and required blood levels of vitamin D and provides recommendations for supplementation of vitamin D in persons with intellectual disabilities.

Potential vitamin D responsive conditions of relevance to those with neuro-developmental disorders and intellectual disabilities include bone metabolism, falls and fractures, physical functioning, infectious diseases (including tuberculosis and respiratory infections),insulin resistance, type 2 diabetes mellitus, cardiovascular diseases, Alzheimer disease, autism, ADHDs, cancer, oral health,and reduction of all-cause mortality.

Evidence suggests that the administration of vitamin D supplements at intervals of greater than once a month has less beneficial effects (and perhaps harm) in preventing falls and fractures (Figure 3) [178-180]. Considering the relatively short half-life of vitamin D, unphysiological fluctuatons of serum and intra-cellular vitamin D levels could explainless benefits with infrequent administration of oral or parenteral vitamin D.

To alleviate various diseases and disorders requires different serum 25(OH)D levels, with certain diseases, such as cancer and autoimmune disorders, requiring higher levels (Table 1). Nevertheless, as with other physiological phenomena, the goal should be to achieve the optimal necessary serum 25(OH)D levels to obtain the most benefit in body tissues to reduce vitamin D-deficiency associated disorders while minimizing potential, albeit rare, adverse effects [181]. Thus, aiming to achieve the middle of the suggested normal range (optimal level) (50 ng/mL) should provide the benefit of achieving serum 25(OH) D levels above 40 ng/mL in most persons with MCDD. Supplementation with vitamin D should be considered together with other micronutrient supplements in vulnerable populations. It can be conveniently provided through food fortification programs [182] to cost-effectively overcome specific diseases or disorders [164].

Because sick people spend more time indoors (thus, producing less vitamin D through exposure to UVB) and live mostly a sedentary lifestyle, the validity of the associations reported between vitamin D and various diseases is not clear. Although lower vitamin D levels are associated with a variety of illnesses, as demonstrated in observational studies, with the exception of musculoskeletal disorders (bone diseases and falls) [183], there currently is not enough evidence from randomized clinical trials that vitamin D supplementation prevents such illnesses.

Persons with MCDD will be benefited by maintaining their serum 25(OH)D levels above 40 ng/ml (100 nmol/L) throughout the year [14], with the recommended range of 40 to 60 ng/mL. Expected7 benefits include elimination of osteomalacia, improvement in mental and physical well-being, lower PTH levels, promotion of healthy BMD with normal bone architecture, reduction of the risks of falls and fractures, enhanced efficacy and safety of antiosteoporosis medications (if needed), reduction of the burden of several disorders that are associated with vitamin D deficiency, and relief from a host of other non-skeletal beneficial effects with minimal cost.


Routine measurement of serum 25(OH)D levels (and associated expenses) may not be justifiable in situations in which most people are likely to be vitamin D deficient, as in the case of residents in nursing homes and developmental disability facilities [10]. Moreover, vitamin D intakes of ≤ 5,000 IU/day do not cause demonstrable adverse effects in adults, while the safe upper limit is considered as 10,000 IU/day.

Considering the broader benefits, cost-effectiveness and minimal adverse effects, we encouraged targeting serum 25(OH)D levels to 40 ng/mL (100 pmol/L) as the lower limit for persons with intellectual disabilities, with the recommended range of 40-60 ng/mL. This can be achieved in over 98% of people with oral vitamin D3 supplements of less than 5,000/day (between 2,000 and 4,000 IU/day) or one gel-caps of 50,000 IU, administer orally, once in two weeks. Optimizing serum vitamin D levels to above 40 ng/mL is likely to decrease burdens from comorbidities and improve overall health.

To avoid fluctuations of serum 25(OH)D levels, vitamin D3 should be administered at a frequency of less than once a month. When there is severe vitamin D deficiency, an appropriate oral loading of dose D3 should be considered [e.g., 4 to 6, 50,000 IU oral capsules or an injectable vitamin D vial containing ~300,000 IU, preferably administered orally (instead of giving IM injections) which would avoid pain and reaching supra-pharmacological vitamin D levels in blood, is a low-cost effective option availableoutside USA]. Unless there is a severe deficiency or major issues with intestinal absorption, parenteral administration should be discouraged.


The author thanks Drs. Philip May and Matt Holder for their assistance in an earlier version of this manuscript.

Conflicts of Interest

This research received no grant from any funding agency in the public, commercial, or not-for-profit sectors. The author has no conflicts of interest.


Select your language of interest to view the total content in your interested language

Viewing options

Post your comment

Share This Article

Flyer image

Post your comment

captcha   Reload  Can't read the image? click here to refresh